These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 1352828)

  • 41. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
    Kirby RS
    Br J Urol; 1998 Sep; 82(3):373-9. PubMed ID: 9772873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
    Diabetologia; 1996 Dec; 39(12):1554-61. PubMed ID: 8960842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of terazosin on blood pressure and serum lipids.
    Gong P; Tang J; Cheng L; Lu Z; Zhang J; Zeng F
    J Tongji Med Univ; 1999; 19(4):291-4. PubMed ID: 12938521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antihypertensive therapy with once-daily administration of terazosin, a new alpha 1-adrenergic-receptor blocker.
    Abraham PA; Halstenson CE; Matzke GR; Napier JL; Keane WF
    Pharmacotherapy; 1985; 5(5):285-9. PubMed ID: 2866492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of terazosin on serum lipids.
    Deger G
    Am J Med; 1986 May; 80(5B):82-5. PubMed ID: 2872813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Mordasini R
    Clin Pharmacol Ther; 1986 Nov; 40(5):525-30. PubMed ID: 2876796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension.
    Webb DJ; Hutcheson MJ; Robertson MP; Murray GD; Lorimer AR; Robertson JI
    Scott Med J; 1985 Apr; 30(2):106-10. PubMed ID: 3892676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The antihypertensive effects of doxazosin: a clinical overview.
    Cox DA; Leader JP; Milson JA; Singleton W
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):83S-90S. PubMed ID: 2939872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Terazosin: an effective once-daily monotherapy for the treatment of hypertension.
    Dauer AD
    Am J Med; 1986 May; 80(5B):29-34. PubMed ID: 2872804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
    Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
    van den Hogen AL
    Am Heart J; 1988 Dec; 116(6 Pt 2):1757-62. PubMed ID: 2904746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension.
    Houston MC; Olafsson L; Burger MC
    Angiology; 1991 Sep; 42(9):681-90. PubMed ID: 1928808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with terazosin administered in combination with other antihypertensive agents.
    Chrysant SG
    Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
    Saunders E
    Am Heart J; 1991 Sep; 122(3 Pt 2):936-42. PubMed ID: 1678925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive value of various parameters for the antihypertensive effect of the beta blocker ICI 66,082 (1).
    Meekers J; Missotten A; Fagard R; Demuynck D; Harvengt C; Pas P; Billiet L; Amery A
    Arch Int Pharmacodyn Ther; 1975 Feb; 213(2):294-306. PubMed ID: 238480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of terazosin in the treatment of essential hypertension in blacks.
    Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
    J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.